Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Romedica LLC

Neither a doctor nor a teaching hospital

Research payments

$226,291

54 payments

Through program year 2022, Romedica LLC is reported as receiving $226,291 in research payments, across 54 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $65,698 28
2021 Research $16,180 4
2020 Research $18,361 5
2019 Research $126,052 17

Breakdown

Who paid Research payments · program years 2019–2022
  1. Ferring International Pharmascience Center US $70,501 9 payments
  2. Ferring Pharmaceuticals AS $56,799 9 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $43,475 18 payments
  4. Genzyme Corporation $26,833 9 payments
  5. Novo Nordisk AS $15,414 3 payments
  6. Sanofi US Services Inc. $13,270 6 payments
Studies the money was for Research payments · program years 2019–2022
  1. A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults $87,162 13 payments
  2. A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $43,475 18 payments
  3. A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults $40,137 5 payments
  4. A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma $20,973 9 payments
  5. Nn2211-4232 $15,414 3 payments
  6. Lung function decline $11,800 1 payment
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $4,100 3 payments
  8. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $3,230 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record